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1. INTRODUCTION AND BACKGROUND {#jcmm13896-sec-0001}
==============================

Lysosome‐associated protein transmembrane‐4 beta (LAPTM4B) has two alleles named as LAPTM4B\*1 and LAPTM4B\*2 (GenBank No. [AY219176](AY219176) and [AY219177](AY219177)). Allele \*1 has a single copy of a 19‐bp sequence in the 5\` untranslated region (5\`UTR), but allele \*2 contains tandem repeats of 19‐bp sequence.[1](#jcmm13896-bib-0001){ref-type="ref"} LAPTM4B gene is located on long chromosome 8 (8q22.1) and contains seven exons that encodes two isoforms of tetratransmembrane proteins, LAPTM4B‐24 and LAPTM4B‐35, with molecular weights of 25 kDa and 35 kDa respectively. The LAPTM4B‐35′s primary structure is formed by 317 amino acid residues, and LAPTM4B‐24 comprised 226 amino acids. LAPTM4B, an integral membrane protein, contains several lysosomal‐targeting motifs at the C terminus and colocalizes with late endosomal and lysosomal markers. LAPTM4B is a proto‐oncogene, which becomes up‐regulated in various cancers. Preceding studies have examined the possible link between LAPTM4B polymorphism and susceptibility to several cancers,[1](#jcmm13896-bib-0001){ref-type="ref"}, [2](#jcmm13896-bib-0002){ref-type="ref"}, [3](#jcmm13896-bib-0003){ref-type="ref"}, [4](#jcmm13896-bib-0004){ref-type="ref"}, [5](#jcmm13896-bib-0005){ref-type="ref"}, [6](#jcmm13896-bib-0006){ref-type="ref"}, [7](#jcmm13896-bib-0007){ref-type="ref"}, [8](#jcmm13896-bib-0008){ref-type="ref"}, [9](#jcmm13896-bib-0009){ref-type="ref"}, [10](#jcmm13896-bib-0010){ref-type="ref"}, [11](#jcmm13896-bib-0011){ref-type="ref"}, [12](#jcmm13896-bib-0012){ref-type="ref"}, [13](#jcmm13896-bib-0013){ref-type="ref"}, [14](#jcmm13896-bib-0014){ref-type="ref"}, [15](#jcmm13896-bib-0015){ref-type="ref"}, [16](#jcmm13896-bib-0016){ref-type="ref"}, [17](#jcmm13896-bib-0017){ref-type="ref"}, [18](#jcmm13896-bib-0018){ref-type="ref"}, [19](#jcmm13896-bib-0019){ref-type="ref"}, [20](#jcmm13896-bib-0020){ref-type="ref"}, [21](#jcmm13896-bib-0021){ref-type="ref"}, [22](#jcmm13896-bib-0022){ref-type="ref"}, [23](#jcmm13896-bib-0023){ref-type="ref"}, [24](#jcmm13896-bib-0024){ref-type="ref"}, [25](#jcmm13896-bib-0025){ref-type="ref"}, [26](#jcmm13896-bib-0026){ref-type="ref"} but the findings are still inconsistent. Hence, the present meta‐analysis was designed to investigate the impact of LAPTM4B polymorphism on risk of cancer.

2. METHODS {#jcmm13896-sec-0002}
==========

A comprehensive search in Web of Science, PubMed, Scopus, and Google Scholar databases was done for all articles describing an association between LAPTM4B polymorphism and cancer risk published up to April 2018. The search strategy was "cancer, carcinoma, tumor, neoplasms," "LAPTM4B, Lysosome‐associated protein transmembrane‐4," and "polymorphism, mutation, variant." Relevant studies included the meta‐analysis if they met the following inclusion criteria: (a) Original case‐control studies that evaluated the LAPTM4B polymorphism and the risk of cancer; (b) studies provided sufficient information of the genotype frequencies of LAPTM4B polymorphism in both cases and controls. The exclusion criteria were: (a) conference abstract, case reports, reviews, duplication data; (b) insufficient genotype information provided.

Data extraction was done by two independently authors. From each study, the following data were collected: the first author\'s name, publication year, country, ethnicity of participants, cancer type, genotyping methods of *LAPTM4B* polymorphism, the sample size, and the genotype and allele frequencies of cases and controls (Table [1](#jcmm13896-tbl-0001){ref-type="table"}).

###### 

Characteristics of all studies included in the meta‐analysis

  Author    Year   Country   Ethnicity   Cancer type                   Source of control   Genotyping method   Case/control   Cases   Controls   HWE                                              
  --------- ------ --------- ----------- ----------------------------- ------------------- ------------------- -------------- ------- ---------- ----- ----- ----- ----- ----- ----- ------ ----- -------
  Chen      2016   China     Asian       Renal cell carcinoma          PB                  PCR                 180/347        83      80         17    246   114   198   131   18    527    167   0.538
  Chen      2016   China     Asian       Bladder cancer                PB                  PCR                 91/347         38      41         12    117   65    198   131   18    527    167   0.538
  Chen      2016   China     Asian       B‐cell lymphoma               PB                  PCR                 162/350        87      64         11    238   86    199   133   18    531    169   0.549
  Cheng     2008   China     Asian       Colon cancer                  HB                  PCR                 253/350        113     112        28    338   168   199   133   18    531    169   0.538
  Cheng     2008   China     Asian       Rectal cancer                 HB                  PCR                 237/350        126     101        10    353   121   199   133   18    531    169   0.539
  Cheng     2008   China     Asian       Oesophageal cancer            HB                  PCR                 211/350        123     80         8     326   96    199   133   18    531    169   0.539
  Deng      2005   China     Asian       Lung cancer                   PB                  PCR                 166/134        54      91         21    199   133   67    59    8     193    75    0.284
  Ding      2018   China     Asian       B‐cell lymphoma               HB                  PCR                 162/350        87      64         11    238   86    199   133   18    531    169   0.538
  Fan       2012   China     Asian       Breast cancer                 HB                  PCR                 732/649        326     342        64    994   470   346   262   41    954    344   0.355
  Hashemi   2014   Iran      Asian       Breast cancer                 HB                  PCR                 311/225        137     163        11    437   185   104   117   4     325    125   0.009
  Hashemi   2016   Iran      Asian       Prostate cancer               HB                  PCR                 168/176        102     55         11    259   77    79    87    10    245    107   0.025
  Li        2006   China     Asian       Lung cancer                   PB                  PCR                 131/104        70      56         5     196   66    57    36    11    150    58    0.155
  Li        2012   China     Asian       Breast cancer                 HB                  PCR                 208/211        90      100        18    280   136   129   76    6     334    88    0.185
  Liu       2007   China     Asian       Gastric cancer                HB                  PCR                 214/350        88      107        19    283   145   199   133   18    531    169   0.483
  Meng      2011   China     Asian       Cervical cancer               HB                  PCR                 317/413        127     153        37    407   227   225   163   28    613    219   0.775
  Meng      2013   China     Asian       Endometrial cancer            HB                  PCR                 283/378        93      135        55    321   245   200   140   38    540    216   0.072
  Meng      2017   China     Asian       Papillary thyroid carcinoma   HB                  PCR                 183/697        90      73         20    253   113   397   264   36    1058   336   0.352
  Qi        2010   China     Asian       Liver cancer                  HB                  PCR                 86/78          27      51         8     105   67    36    34    7     106    48    0.798
  Shaker    2015   Egypt                 Breast cancer                 HB                  PCR                 88/80          36      40         12    112   64    45    29    6     119    41    0.661
  Sun       2007   China     Asian       Lymphoma                      HB                  PCR                 166/350        72      71         23    215   117   199   133   18    531    169   0.549
  Sun       2008   China     Asian       Liver cancer                  PB                  PCR                 190/175        72      110        8     254   126   99    67    9     265    85    0.586
  Tang      2014   China     Asian       NSCLC                         HB                  PCR                 392/437        158     171        63    487   297   226   176   35    628    246   0.928
  Wang      2010   China     Asian       Pancreatic cancer             HB                  PCR                 58/156         24      26         8     74    42    74    67    15    215    97    0.976
  Wang      2012   China     Asian       Liver cancer                  HB                  PCR                 303/515        107     156        40    370   236   272   205   38    749    281   0.941
  Wang      2013   China     Asian       Nasopharyngeal carcinoma      HB                  PCR                 134/327        74      48         12    196   72    163   145   19    471    183   0.69
  Wang      2017   China     Asian       Pancreatic cancer             HB                  PCR                 233/842        98      116        19    312   154   435   350   57    1220   464   0.231
  Xu        2012   China     Asian       Ovarian cancer                HB                  PCR                 282/365        122     115        45    359   205   231   108   26    570    160   0.009
  Yang      2012   China     Asian       Gallbladder cancer            HB                  PCR                 91/155         34      45         12    113   69    88    57    10    233    77    0.850
  Zhai      2012   China     Asian       Hepatocellular carcinoma      HB                  PCR                 102/135        37      52         13    126   78    ---   ---   ---   205    65    ---
  Zhang     2014   China     Asian       Malignant melanoma            HB                  PCR                 220/617        101     102        17    304   136   336   246   35    918    316   0.248
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Meta‐analysis was carried out using Revman 5.3 software (Copenhagen: The Cochrane Collaboration, 2014, The Nordic Cochrane Centre) and [stata]{.smallcaps} 14.1 software (Stata Corporation, College Station, TX, USA). For each study, Hardy‐Weinberg equilibrium (HWE) was determined by the chi‐squared test, in order to verify the representativeness of the study population.

The association between *LAPTM4B* polymorphism in relation to cancer risk was evaluated by pooled odds ratios (ORs) and their 95% confidence intervals (CIs). Pooled ORs and their 95% CIs for codominant, dominant, recessive, overdominant and the allelic comparison genetic inheritance models were calculated. The significance of the pooled OR was assessed by the *Z* test, and *P* \< 0.05 was considered statistically significant. The choice of using fixed or random effects model was determined by the results of the between‐study heterogeneity test, which was measured using the *Q* test and *I* ^2^ statistic. If the test result was *I* ^2^ ≥ 50% or P~Q~ \< 0.1, indicating the presence of heterogeneity, the random effect model was selected; otherwise, the fixed‐effects model was chosen.

The funnel plot was used to estimate the publication bias. The degree of asymmetry was measured using Egger\'s test; *P* \< 0.05 was considered significant publication bias. To measure the potential influence of each study on the overall effect size, sensitivity analysis was performed.

3. RESULTS {#jcmm13896-sec-0003}
==========

The characteristics and relevant data of the included studies are shown in Table [1](#jcmm13896-tbl-0001){ref-type="table"}. The results of the meta‐analysis revealed a significant association between *LAPTM4B* polymorphism and cancer susceptibility cancer in codominant (OR = 1.42, 95% CI = 1.27‐1.59, *P* \< 0.00001, \*1/2 vs \*1/1; OR = 2.01, 95% CI = 1.69‐2.39, *P* \< 0.00001, \*2/2 vs \*1/1), dominant (OR = 1.50, 95% CI = 1.34‐1.69, *P* \< 0.00001, \*1/2 + \*2/2 vs \*1/1), recessive (OR = 1.73, 95% CI = 1.53‐1.95, *P* \< 0.00001, \*2/2 vs \*1/1 + \*1/2), overdominant (OR = 1.28, 95% CI = 1.17‐1.41, *P* \< 0.00001, \*1/2 vs \*1/1 + \*2/2), and allele (OR = 1.40, 95% CI = 1.28‐1.53, *P* \< 0.00001, \*2 vs \*1) inheritance model tested (Figure [1](#jcmm13896-fig-0001){ref-type="fig"}).

![The pooled ORs and 95% CIs for the association between LAPTM4B polymorphism and cancer susceptibility. The forest plot for relationship between LAPTM4B polymorphism and cancer susceptibility for \*2/2 vs \*1/1 (A), \*2/2 vs \*1/1 (B), \*1/2 + \*2/2 vs \*1/1 (C), \*2/2 vs \*1/2 + \*1/1 (D), \*1/2 vs \*1/1 + \*2/2 (E), and \*2 vs \*1 (F)](JCMM-22-6396-g001){#jcmm13896-fig-0001}

Stratifying according to cancer types proposed that LAPTM4B polymorphism significantly increased the risk of breast cancer, gastrointestinal cancer, gynaecological cancer, liver cancer, lung cancer, and lymphoma (data not shown).

The potential publication bias was evaluated using a Begg\'s funnel plot and Egger\'s test and the analysis suggested no publication bias for this meta‐analysis of the heterozygous codominant, dominant, recessive, overdominanat, and allele model (all *P*‐values for bias \>0.05). We executed sensitivity analysis by neglecting a single study each time to reflect the influence of the individual data set to the pooled OR. The results indicated that the significance of pooled ORs for LAPTM4B polymorphism was not extremely influenced, suggesting the stability and reliability of the results in this meta‐analysis.

4. DISCUSSION {#jcmm13896-sec-0004}
=============

In the current study, we performed a meta‐analysis to find out the exact role of LAPTM4B polymorphism on risk of cancer. The results revealed that LAPTM4B polymorphism significantly increased the risk of cancer in codominant, dominant, overdominant, and allele genetic inheritance models. Stratification by cancer types suggested that LAPTM4B polymorphism is associated with the risk of breast cancer, gynaecological cancer, gastrointestinal cancer, liver cancer, lung cancer, and lymphoma. LAPTM4B is a proto‐oncogene that is overexpressed in various types of cancers. It has been proposed that overexpression of LAPTM4B‐35 promote proliferation, invasion, and migration. Its up‐regulation might be caused by gene amplification as well as transcriptional up‐regulation. LAPTM4B alleles have the same sequence except for one 19‐bp fragment for LAPTM4B \*1 and two tight tandem fragments for LAPTM4B \*2 in the 5′UTR of exon 1.[23](#jcmm13896-bib-0023){ref-type="ref"} The 19‐bp alteration in 5′UTR of the first exon of the LAPTM4B gene can shift the open reading frame (ORF), resulting in two alternate protein isoforms, LAPTM4B‐35 and LAPTM4B‐40. In conclusion, the finding of this meta‐analysis illustrated that LAPTM4B polymorphism may affect the risk of development of cancers.
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